Diode Laser Cyclophotocoagulation

Mandal, Shramana; Gadia, Ritu; Ashar, Jatin

doi:10.5005/jp-journals-10008-1015

Cited by 4 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2,3 Transscleral cyclophotocoagulation (TS-CPC) is currently a widely employed method of ciliary body ablation that reduces aqueous humor formation by destroying the ciliary body and ciliary epithelium using a continuous diode laser energy source. 4 In its most common form, TS-CPC employs an 810 nm semiconductor diode laser, the energy of which has been shown to be absorbed by melanin in the ciliary epithelium. During this process, the surrounding tissues including the ciliary body and its vascular supply are destroyed by the resultant thermal energy transfer.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of 180° Cyclodiode Transscleral Photocoagulation for Refractory Glaucoma

Mocan

Kocabeyoğlu

et al. 2018

tjo

View full text Add to dashboard Cite

Objectives:To evaluate the efficacy and safety of transscleral cyclophotocoagulation (TS-CPC) limited to 180° of ciliary body ablation in patients with various forms of refractory glaucoma.Materials and Methods:Thirty eyes with refractory glaucoma treated with 180° TS-CPC were retrospectively analyzed for intraocular pressure (IOP) reduction and success rates. Patients’ age, gender, type of glaucoma, number of diode laser treatment sessions, postoperative complications, number of hypotensive medications required to control IOP, and best corrected visual acuity (BCVA) were evaluated. The criteria for success were defined as postoperative IOP <21 mmHg or >20% decrease in IOP with or without additional medical treatment.Results:The mean age of all patients was 51.3±26.9 years (range,1-84 years). The mean postoperative IOP level (23.9±8.5 mmHg) was significantly lower than preoperative IOP (39.2±8.9 mmHg) (p<0.001). The success rate was 66.6% after the first laser treatment and reached 86.7% following repeat laser treatments over an average follow-up period of 22.2±19.9 months. The need for topical hypotensive medications decreased from 2.8±1.0 preoperatively to 2.4±1.3 following TS-CPC (p=0.048). Two patients (6.6%) had a one-line decrease in their BCVA following TS-CPC. Transient hypotony and hyphema developed in 4 patients (13.3%). Total laser energy delivered did not correlate with either preoperative (rho=0.10; p=0.594) or postoperative IOP (rho=0.21; p=0.260).Conclusion:TS-CPC limited to 180° of ciliary body ablation is associated with a reasonable success rate and low incidence of adverse effects in patients with refractory glaucoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of 180° Cyclodiode Transscleral Photocoagulation for Refractory Glaucoma

Mocan

Kocabeyoğlu

et al. 2018

tjo

View full text Add to dashboard Cite

show abstract

“…The utilization of TSCPC is constrained by the occurrence of post-treatment complications, which can vary in severity. TSCPC is frequently regarded as a final option for managing refractory glaucoma, particularly in cases characterized by limited visual potential or when patients are unsuitable candidates for incisional surgery [6,10].…”

Section: Introductionmentioning

confidence: 99%

A Case Series of Transscleral Cyclophotocoagulation Nd:YAG Laser in Refractory Glaucoma

Lo Giudice,

Miceli,

Tumminello

et al. 2023

JCTO

View full text Add to dashboard Cite

Purpose: To describe the efficacy and safety of surgical treatment in refractory glaucoma using transscleral cyclophotocoagulation with a diode laser (TSCPC). Cyclo-G6 laser with a G-probe delivery system (Iridex, Silicon Valley, CA, USA). Materials and Methods: 134 patients (134 eyes) with refractory glaucoma were included in this study. Patients received transscleral cyclophotocoagulation (TSCPC) using the IRIDEX Cyclo-G6 diode laser equipped with a G-probe delivery system. The eyes were treated with 1250–1500 mW for 3500–4000 ms depending on the iris colour. Intraocular pressure (IOP) and the count of antiglaucoma medications (AGM) were documented at the initial assessment and again at 3, 6, and 12 months following the treatment. Results: A reduction in IOP was observed in 97.73% of eyes at 12 months. At 12 months, 55.97% of the 134 eyes decreased IOP under 21 mmHg. At the 3-month mark, 96.27% of eyes attained an IOP reduction in 30% or more from their initial baseline levels, 85.61% at 6 months, and 82.17% at 12 months. A reduction in AGM was recorded for 86.07% of patients at 6 months and 87.31% at 12 months. There were no instances of severe complications reported, and minor complications were observed in 3% (4 out of 134) of the treated eyes. Conclusions: IRIDEX Cyclo-G6 laser is a surgical method effective in reducing IOP in patients with refractory glaucoma

show abstract

Diode laser cyclophotocoagulation in Indian eyes: efficacy and safety

2016

View full text Add to dashboard Cite

Diode laser cyclophotocoagulation (DLCP) has emerged as a time-tested procedure for end-stage glaucoma with fewer complications. By means of this study, we have evaluated its wide indications, its efficacy, and safety in darkly pigmented Asian Indian eyes. Ninety-one eyes with uncontrolled glaucoma presenting to glaucoma clinic of a tertiary care center over a period of 6 years were scheduled for DLCP. The semiconductor diode laser with a G probe was used with laser energy delivered about 1.5 mm behind the surgical limbus. The extent of clock hours of laser application was determined by pretreatment intraocular pressure (IOP) and superior area was spared in cases where future filtration surgery was contemplated. The DLCP was repeated earliest at 1 month in case of non-response and a maximum of three laser procedures were performed for any patient. Ninety-one eyes of 89 patients (40 males, 49 females) were included. Common indications included secondary glaucoma (37.3 %), failed trabeculectomies (27.4 %), angle closure glaucoma (17.5 %), etc. Laser power delivered ranged from 990 to 1800 mW, (mean 1396 + 182.14 mW) with an average of 17 spots. Patients improved from pretreatment IOP of 38.18 + 8.96 mmHg (range 20.6-64) to post treatment IOP of 17.86 + 7.75 mmHg (range 10-42). Qualified success was defined as final IOP of 20 mm Hg or less on topical medications that could be achieved in 70 % eyes with one or repeat treatment. Pre op visual acuity ranged from PL+ to 6/18 showing a slight improvement to PL+ to 6/12 post op. A 58.5 % reduction of IOP was noted. No incidence of serious complications was noted during follow-up ranging from 9 months to 3 years. DLCP is an effective and safe tool to be used in Indian population for control of IOP. It can be safely used as a primary modality to bring IOP to permissible levels before trabeculectomy.

show abstract

Diode Laser Cyclophotocoagulation

Cited by 4 publications

References 82 publications

Efficacy of 180° Cyclodiode Transscleral Photocoagulation for Refractory Glaucoma

Efficacy of 180° Cyclodiode Transscleral Photocoagulation for Refractory Glaucoma

A Case Series of Transscleral Cyclophotocoagulation Nd:YAG Laser in Refractory Glaucoma

Diode laser cyclophotocoagulation in Indian eyes: efficacy and safety

Contact Info

Product

Resources

About